113 results
10-K
2023 FY
EX-10.6
INTI
Inhibitor Therapeutics, Inc.
Annual report
29 Mar 24
4:05pm
8-K
EX-10.1
INTI
Inhibitor Therapeutics, Inc.
18 Oct 23
Departure of Directors or Certain Officers
9:54am
8-K
EX-10.3
INTI
Inhibitor Therapeutics, Inc.
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.2
INTI
Inhibitor Therapeutics, Inc.
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.1
INTI
Inhibitor Therapeutics, Inc.
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.4
b4zslmit2li m8pe
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.1
hy9hh g6y90bs
18 Jan 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.1
mu7 kw6c91wie98tc
17 Dec 20
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-10.1
b7cgp5965oyz1
6 May 20
Entry into a Material Definitive Agreement
4:32pm
8-K
EX-10.2
07gaz4c76 yy
31 Dec 18
Entry into a Material Definitive Agreement
5:16pm
8-K
EX-10.1
9zxsz531m4f5k739h2
31 Dec 18
Entry into a Material Definitive Agreement
5:16pm
8-K
EX-10.1
7si2iq
11 Jan 18
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
12:00am
8-K
EX-10.2
rgmmi
11 Jan 18
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
12:00am